Diagnosis and treatment of male patients with lower urinary tract symptoms in Spain - The MERCURY Study. Do urologists follow the recommendations of the European guidelines?

被引:2
作者
Errando-Smet, C. [1 ]
Muller-Arteaga, C. [2 ]
Hernandez, M. [3 ]
Roset, M. [4 ]
机构
[1] Fundacio Puigvert, Serv Urol, Unidad Urol Func & Femenina, Barcelona, Spain
[2] Complexo Hosp Univ Ourense, Dept Urol, Orense, Spain
[3] Astellas Pharma SA, Dept Med Urol, Madrid, Spain
[4] IQVIA, Hlth Econ & Outcomes Res, Barcelona, Spain
来源
ACTAS UROLOGICAS ESPANOLAS | 2018年 / 42卷 / 05期
关键词
Lower urinary tract symptoms; Alpha-blocker; Muscarinic antagonists; Health-related quality of life; Urinary tract symptoms in men; QUALITY-OF-LIFE; OVERACTIVE BLADDER; CLINICAL-PRACTICE; MEN; PREVALENCE; IMPLEMENTATION; INCONTINENCE; VALIDATION; COUNTRIES; STORAGE;
D O I
10.1016/j.acuro.2017.12.003
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Objectives: To explore the management of lower urinary tract symptoms (LUTS) in men in Spain and assess the compliance with recommendations established in the European Association of Urology (EAU) guidelines. Material and methods: MERCURY was an epidemiological and cross-sectional study which involved 227 Urology Units across Spain assessing adult male patients with mixed LUTS and persisting storage symptoms. Sociodemographic, clinical and resource use data for the 6 months prior to study inclusion were collected. Additionally, through a theoretical clinical case, clinicians described their attitude toward the diagnostic and therapeutic management of males with mixed LUTS and persisting storage symptoms during the first and second visits. Answer options given to clinicians about LUTS management were aligned with those recommended by EAU guidelines. Result: 610 patients included in the study were evaluated. 87.7% of them consumed some health resource mainly due to: urologist visits (79.7%), PSA determination (76.6%) and treatment with alpha-blockers (37.5%) and alpha-blockers plus antimuscarinics (37.2%). According to the theoretical clinical case, urologists preference toward diagnostic tools and pharmacological treatment in first visit were mainly PSA determination (97.7%), digital rectal examination (91.4%) and treatment with alphablockers as monotherapy (56.6%), whereas in the second visit uroflowmetry (48.9%), voiding diary (40.3%) and treatment with alpha-blockers plus antimuscarinics (70.6%) were mainly preferred. Conclusions: Urologists attitude toward management of male patients with mixed LUTS and persisting storage symptoms is aligned with that recommended in the EAU guidelines. (C) 2018 AEU. Published by Elsevier Espana, S.L.U. All rights reserved.
引用
收藏
页码:323 / 330
页数:8
相关论文
共 21 条
  • [1] The standardisation of terminology in lower urinary tract function: Report from the standardisation sub-committee of the International Continence Society (Reprinted from Neurourology and Urodynamics, vol 21, pg 167-178, 2002)
    Abrams, P
    Cardozo, L
    Fall, M
    Griffiths, D
    Rosier, P
    Ulmsten, U
    Van Kerrebroeck, P
    Victor, A
    Wein, A
    [J]. UROLOGY, 2003, 61 (01) : 37 - 49
  • [2] Guzmán SA, 2009, ACTAS UROL ESP, V33, P902
  • [3] Arlandis S, 2012, CLIN DRUG INVEST, V32, P523, DOI 10.2165/11633760-000000000-00000
  • [4] Design and validation of a new screening instrument for lower urinary tract dysfunction: The bladder control self-assessment questionnaire (B-SAQ)
    Basra, Ramandeep
    Artibani, Walter
    Cardozo, Linda
    Castro-Diaz, Dauid
    Chapple, Christopher
    Cortes, Eduardo
    De Ridder, Dirk
    Pons, Montse Espuna
    Haab, Francois
    Hohenfellner, Markus
    Kirby, Michael
    Milsom, Ian
    Van Kerrebroeck, Philip
    Vierhout, Mark
    Wagg, Adrian
    Kelleher, Cornelius
    [J]. EUROPEAN UROLOGY, 2007, 52 (01) : 230 - 238
  • [5] Profile of Lower Urinary Tract Symptoms in the Male and Their Impact on Quality of Life
    Cambronero, J.
    Arlandis, S.
    Errando, C.
    Mora, A. M.
    [J]. ACTAS UROLOGICAS ESPANOLAS, 2013, 37 (07): : 401 - 407
  • [6] Errando-Smet C, 2017, NEUROUROL URODYNAM, V9999, P1
  • [7] Espuna Pons M, 2006, Actas Urol Esp, V30, P1017
  • [8] Pharmacological Treatment of Lower Urinary Tract Symptoms in Men: Implementation of Recommendations in Clinical Practice
    Esteban, M.
    Castro, D. M.
    [J]. ACTAS UROLOGICAS ESPANOLAS, 2013, 37 (06): : 330 - 337
  • [9] Gravas S, 2017, EUROPEAN ASS UROLOGY
  • [10] Grupo Espanol de Urodinamica de SINUG, 2005, ACTAS UROL ESP, V29, P16